Cellectis, Janssen, and others plunge into cell therapy with the help of several genome-editing technologies, including TALENs and CRISPR/Cas9.
NIH Director Francis Collins today posted a position statement outlining a policy not to fund any use of gene editing technologies in human embryos.
Scientists from Emory University have found that Cas9 from Francisella novicida can inhibit viral protein production.
The data show that Phytophthora pathogens evolved effectors that bind to a conserved plant protein that controls small RNA biogenesis and processing.
The unique characteristics of mitochondrial genomes and diseases add a twist to the current discussions about heritable edits to the genome.
In Science this week: factors influencing retrotransposon integration sites, and more.
A bioethicist argues for the responsible use of germline gene editing.
Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.
Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.